Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus
Imperial College London
150 participants
Apr 1, 2021
INTERVENTIONAL
Conditions
Summary
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.
Eligibility
Inclusion Criteria3
- eligible for bariatric surgery according to NICE guidelines (GC 189)
- Type 2 diabetes mellitus
- BMI \>30kg/m2
Exclusion Criteria7
- Recent hospitalisation in the past 30 days
- Recurrent hypoglycaemic episodes
- Recurrent hypotensive episodes
- Contraindications to bariatric surgery
- Previous bariatric surgery
- Current pregnancy
- Breastfeeding
Interventions
Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids
Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04432025